Effects of a 6-month dietary-induced weight loss on erythrocyte membrane omega-3 fatty acids and hepatic status of subjects with nonalcoholic fatty liver disease : The Fatty Liver in Obesity study
Copyright © 2020 National Lipid Association. Published by Elsevier Inc. All rights reserved..
BACKGROUND: Omega-3 polyunsaturated fatty acids (PUFAs) have been suggested as important biomolecules in the management of nonalcoholic fatty liver disease (NAFLD).
OBJECTIVE: This study aimed to evaluate the effect of 6-month weight loss diets on erythrocyte membrane omega-3 PUFA composition of NAFLD adults, and to evaluate the potential relationship between erythrocyte membrane omega-3 PUFAs and hepatic health markers.
METHODS: In this secondary analysis of the Fatty Liver in Obesity study, erythrocyte membranes were analyzed by gas chromatography in 54 subjects with liver steatosis detected by ultrasonography who achieved a weight loss >5% after the follow-up. Baseline and 6-month evaluation included hepatic acoustic radiation force impulse elastography and magnetic resonance imaging, anthropometry, body composition, and biochemical determinations.
RESULTS: After the follow-up, α-linolenic acid (ALA) proportion significantly increased in erythrocyte membranes, whereas eicosapentaenoic acid (EPA) showed no statistical difference and docosapentaenoic acid decreased. Both the changes in erythrocyte membrane ALA and EPA were positively associated with dietary ALA. Regression analyses evidenced that the changes in erythrocyte membrane ALA and EPA were inversely associated with the changes in liver stiffness and liver iron content, respectively.
CONCLUSION: The adherence to weight loss strategies for 6 months led to changes in erythrocyte membrane omega-3 PUFA composition, which in turn were associated with changes in hepatic markers, suggesting that these fatty acids accompany the improvements in the liver during a dietary treatment. These findings show that beyond weight loss, the composition of the diet has an important role in the management of NAFLD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Journal of clinical lipidology - 14(2020), 6 vom: 16. Nov., Seite 837-849.e2 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Marin-Alejandre, Bertha Araceli [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ALA |
|---|
| Anmerkungen: |
Date Completed 26.08.2021 Date Revised 26.08.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jacl.2020.08.007 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM315341475 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM315341475 | ||
| 003 | DE-627 | ||
| 005 | 20231225154715.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jacl.2020.08.007 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1051.xml |
| 035 | |a (DE-627)NLM315341475 | ||
| 035 | |a (NLM)32962964 | ||
| 035 | |a (PII)S1933-2874(20)30252-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Marin-Alejandre, Bertha Araceli |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effects of a 6-month dietary-induced weight loss on erythrocyte membrane omega-3 fatty acids and hepatic status of subjects with nonalcoholic fatty liver disease |b The Fatty Liver in Obesity study |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.08.2021 | ||
| 500 | |a Date Revised 26.08.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 National Lipid Association. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Omega-3 polyunsaturated fatty acids (PUFAs) have been suggested as important biomolecules in the management of nonalcoholic fatty liver disease (NAFLD) | ||
| 520 | |a OBJECTIVE: This study aimed to evaluate the effect of 6-month weight loss diets on erythrocyte membrane omega-3 PUFA composition of NAFLD adults, and to evaluate the potential relationship between erythrocyte membrane omega-3 PUFAs and hepatic health markers | ||
| 520 | |a METHODS: In this secondary analysis of the Fatty Liver in Obesity study, erythrocyte membranes were analyzed by gas chromatography in 54 subjects with liver steatosis detected by ultrasonography who achieved a weight loss >5% after the follow-up. Baseline and 6-month evaluation included hepatic acoustic radiation force impulse elastography and magnetic resonance imaging, anthropometry, body composition, and biochemical determinations | ||
| 520 | |a RESULTS: After the follow-up, α-linolenic acid (ALA) proportion significantly increased in erythrocyte membranes, whereas eicosapentaenoic acid (EPA) showed no statistical difference and docosapentaenoic acid decreased. Both the changes in erythrocyte membrane ALA and EPA were positively associated with dietary ALA. Regression analyses evidenced that the changes in erythrocyte membrane ALA and EPA were inversely associated with the changes in liver stiffness and liver iron content, respectively | ||
| 520 | |a CONCLUSION: The adherence to weight loss strategies for 6 months led to changes in erythrocyte membrane omega-3 PUFA composition, which in turn were associated with changes in hepatic markers, suggesting that these fatty acids accompany the improvements in the liver during a dietary treatment. These findings show that beyond weight loss, the composition of the diet has an important role in the management of NAFLD | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a ALA | |
| 650 | 4 | |a EPA | |
| 650 | 4 | |a FLiO | |
| 650 | 4 | |a Liver iron | |
| 650 | 4 | |a Liver stiffness | |
| 650 | 4 | |a NAFLD | |
| 650 | 4 | |a Omega-3 | |
| 650 | 4 | |a Weight loss | |
| 650 | 7 | |a Fatty Acids, Omega-3 |2 NLM | |
| 700 | 1 | |a Abete, Itziar |e verfasserin |4 aut | |
| 700 | 1 | |a Monreal, J Ignacio |e verfasserin |4 aut | |
| 700 | 1 | |a Elorz, Mariana |e verfasserin |4 aut | |
| 700 | 1 | |a Benito-Boillos, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Herrero, José Ignacio |e verfasserin |4 aut | |
| 700 | 1 | |a Navarro-Blasco, Iñigo |e verfasserin |4 aut | |
| 700 | 1 | |a Tur, Josep A |e verfasserin |4 aut | |
| 700 | 1 | |a Bandarra, Narcisa M |e verfasserin |4 aut | |
| 700 | 1 | |a Zulet, M Angeles |e verfasserin |4 aut | |
| 700 | 1 | |a Martinez, J Alfredo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical lipidology |d 2007 |g 14(2020), 6 vom: 16. Nov., Seite 837-849.e2 |w (DE-627)NLM175693773 |x 1933-2874 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2020 |g number:6 |g day:16 |g month:11 |g pages:837-849.e2 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jacl.2020.08.007 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2020 |e 6 |b 16 |c 11 |h 837-849.e2 | ||